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Summary 
Background Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma 
of the head and neck have few treatment options and poor prognosis. Nivolumab significantly 
improved survival of this patient population when compared with standard single-agent therapy 
of investigator’s choice in Checkmate 141; here we report the effect of nivolumab on patient-
reported outcomes (PROs). 
Methods CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent 
or metastatic squamous cell carcinoma of the head and neck who progressed within 6 months 
after platinum-based chemotherapy. Patients were randomly assigned (2:1) to nivolumab 3 
mg/kg every 2 weeks (n=240) or investigator’s choice (n=121) of methotrexate (40–60 mg/m² of 
body surface area), docetaxel (30–40 mg/m²), or cetuximab (250 mg/m² after a loading dose of 
400 mg/m²) until disease progression, intolerable toxicity, or withdrawal of consent. On Jan 26, 
2016, the independent data monitoring committee reviewed the data at the planned interim 
analysis and declared overall survival superiority for nivolumab over investigator’s choice 
therapy (primary endpoint; described previously). The protocol was amended to allow patients in 
the investigator’s choice group to cross over to nivolumab. All patients not on active therapy are 
being followed for survival. As an exploratory endpoint, PROs were assessed at baseline, week 
9, and every 6 weeks thereafter using the European Organisation for Research and Treatment 
of Cancer (EORTC) Quality of Life Questionnaire–Core 30 (QLQ-C30), the EORTC head and 
neck cancer-specific module (EORTC QLQ-H&N35), and the three-level European Quality of 
Life–5 Dimensions (EQ-5D) questionnaire. Differences within and between treatment groups in 
PROs were analysed by ANCOVA among patients with baseline and at least one other 
assessment. All randomised patients were included in the time to clinically meaningful 
deterioration analyses. Median time to clinically meaningful deterioration was analysed by 
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Kaplan-Meier methods. CheckMate 141 was registered with ClinicalTrials.org, number 
NCT02105636.  
Findings Patients were enrolled between May 29, 2014, and July 31, 2015, and subsequently 
361 patients were randomly assigned to receive nivolumab (n=240) or investigator’s choice 
(n=121). Among them, 129 patients (93 in the nivolumab group and 36 in the investigator’s 
choice group) completed any of the PRO questionnaires at baseline and at least one other 
assessment. Treatment with nivolumab resulted in adjusted mean changes from baseline to 
week 15 ranging from −2·1 to 5·4 across functional and symptom domains measured by the 
EORTC QLQ-C30, with no domains indicating clinically meaningful deterioration. By contrast, 
eight (53%) of the 15 domains in the investigator’s choice group showed clinically meaningful 
deterioration (10 points or more) at week 15 (change from baseline range, −24·5 to 2·4). 
Similarly, on the EORTC QLQ-H&N35, clinically meaningful worsening at week 15 was seen in 
no domains in the nivolumab group and eight (44%) of 18 domains in the investigator’s choice 
group. Patients in the nivolumab group had a clinically meaningful improvement (according to a 
difference of 7 points or greater) in adjusted mean change from baseline to week 15 on the EQ-
5D visual analogue scale, in contrast to a clinically meaningful deterioration in the investigator’s 
choice group (7·3 vs −7·8). Differences between groups were significant and clinically 
meaningful at weeks 9 and 15 in favour of nivolumab for role functioning, social functioning, 
fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C30 and pain and sensory problems 
on the EORTC QLQ-H&N35. Median time to deterioration was significantly longer with 
nivolumab versus investigator’s choice for 13 (37%) of 35 domains assessed across the three 
questionnaires. 
Interpretation In this exploratory analysis of CheckMate 141, nivolumab stabilised symptoms 
and functioning from baseline to weeks 9 and 15, whereas investigator’s choice led to clinically 
meaningful deterioration. Nivolumab delayed time to deterioration of patient-reported quality-of-
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life outcomes compared with single-agent therapy of investigator’s choice in patients with 
platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck. In 
view of the major unmet need in this population and the importance of maintaining or improving 
quality of life for patients with recurrent or metastatic squamous cell carcinoma of the head and 
neck, these data support nivolumab as a new standard-of-care option in this setting. 
Funding Bristol-Myers Squibb. 
 
Research in context  
Evidence before this study 
We searched prospective clinical trial publications indexed in PubMed during the past 10 years 
(Dec 1, 2006, to Dec 1, 2016) for the title or abstract terms “head and neck” and “carcinoma” or 
“cancer” and “quality of life” and “recurrent”, or “metastatic”. The search returned 15 
publications, most of which used chemotherapy-based combinations. Among platinum-
refractory patients, no treatment was noted as having significant improvements on quality of life. 
The search returned only one report on quality of life in a trial investigating the use of a 
checkpoint inhibitor for squamous cell carcinoma of the head and neck: the phase 3 CheckMate 
141 study, which compared nivolumab with single-agent therapy of investigator’s choice in 
patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In 
CheckMate 141, overall survival was significantly longer for patients treated with nivolumab than 
for those treated with investigator’s choice. Grade 3 or 4 treatment-related adverse events were 
less frequent with nivolumab versus investigator’s choice. The study reported that mean 
changes from baseline in patient-reported outcome (PRO) domains assessed on the European 
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–
Core 30 (QLQ-C30) and the EORTC head and neck cancer–specific module (EORTC QLQ-
CheckMate 141 PRO  Harrington et al. 
 
Page 5 of 49 
 
H&N35) were stable for patients treated with nivolumab and deteriorated for patients treated 
with investigator’s choice. 
 
Added value of this study 
Our study provides complete CheckMate 141 patient-reported quality of life analyses for the 
overall population and subgroups of clinical interest. To our knowledge, this is the first study 
showing PROs from a clinical trial assessing a checkpoint inhibitor antibody in patients with 
recurrent or metastatic squamous cell carcinoma of the head and neck. Patients treated with 
nivolumab maintained baseline levels of quality of life, as assessed by three validated PRO 
measures. By contrast, investigator’s choice led to clinically meaningful deteriorations. 
Nivolumab treatment led to a significant delay in deterioration across a number of quality of life 
domains compared with investigator’s choice. 
 
Implications of all the available evidence 
Combined with the primary report from CheckMate 141, results from this study indicate that 
treatment with nivolumab offers a new therapeutic approach to extend survival that might also 
preserve or enhance quality of life in patients with advanced squamous cell carcinoma of the 
head and neck. 
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Introduction 
Squamous cell carcinoma of the head and neck, including cancers of the oral cavity, pharynx, 
and larynx, and its treatment have a major effect on patient quality of life.1 Damage to anatomic 
structures involved in speech, swallowing, and breathing can be caused by the tumour itself or 
can occur as the result of surgical resection, chemoradiotherapy, or both.2 Consequently, 
changes to basic physical functions, physical appearance, and social interactions are common 
among patients with squamous cell carcinoma of the head and neck.3 Patients with squamous 
cell carcinoma of the head and neck have been shown to bear greater psychological distress 
than those patients with many other cancer types because of treatment-related facial 
disfigurement or impaired speech, breathing, eating, or drinking.4 
In addition to negative effects on quality of life, patients with recurrent or metastatic 
squamous cell carcinoma of the head and neck have a dismal prognosis. Median overall 
survival for patients who progress after platinum therapy for primary or recurrent disease is 6 
months or less.5,6 Patient-reported outcomes (PROs) have been collected to assess quality of 
life in a small number of clinical trials of chemotherapy and targeted therapies in recurrent or 
metastatic squamous cell carcinoma of the head and neck, few of which have shown 
improvements or significant differences between treatment groups.7–10 However, baseline 
quality of life scores have been reported to be independent prognostic factors for overall survival 
in patients with recurrent or metastatic head and neck cancer.11 Therefore, there is a large 
unmet medical need for treatments that improve prognosis as well as preserve and maximise 
quality of life. 
Because squamous cell carcinoma of the head and neck recurrence and metastasis are 
enabled by tumour immune evasion, mediated in part by the T cell-suppressive programmed 
death (PD)-1 immune checkpoint, PD-1 inhibitors are of clinical interest in this setting. 
Nivolumab is a fully human IgG4 PD-1 inhibitor antibody that disrupts PD-1-mediated signalling 
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to restore antitumour immunity. This strategy has been shown to be clinically effective in a 
variety of solid tumour types, including squamous cell carcinoma of the head and neck.12–16  
In CheckMate 141, nivolumab showed improved overall survival compared with single-
agent therapy of investigator’s choice in patients with recurrent or metastatic squamous cell 
carcinoma of the head and neck.16 Median overall survival was 7·5 months (95% CI 5·5–9·1) 
with nivolumab and 5·1 months (4·0–6·0) with investigator’s choice (HR 0·70 [97·73% CI 0·51–
0·96]; p=0·01). Estimated 1-year survival was more than doubled with nivolumab compared with 
investigator’s choice (36·0% [95% CI 28·5–43·4] vs 16·6% [8·6–26·8]). Grade 3 or 4 treatment-
related adverse events occurred in 13% of patients treated with nivolumab compared with 35% 
of those treated with investigator’s choice. Moreover, a preliminary analysis of PROs showed 
that nivolumab stabilised quality of life, by contrast with clinically meaningful deterioration 
observed in patients treated with investigator’s choice. Here, we report the full quality-of-life 
analysis based on three widely used, validated PRO questionnaires completed by patients in 
the CheckMate 141 study. 
 
Methods 
Study design and participants 
CheckMate 141 was an international, phase 3, randomised, open-label study designed to 
investigate whether nivolumab improves survival in patients with platinum-refractory recurrent or 
metastatic squamous cell carcinoma of the head and neck compared with single-agent therapy 
of investigator’s choice. Patients were randomly assigned to treatment at 66 sites in 15 
countries in North America, Asia, Europe, and South America (appendix p 2). Full details of the 
study design were previously reported.16 
Eligibility criteria included: histologically confirmed squamous cell carcinoma of the oral 
cavity, pharynx, or larynx (including metastatic disease) that was not amenable to curative 
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treatment and had progressed or recurred within 6 months of the last dose of platinum-based 
chemotherapy; aged 18 years or older; an Eastern Cooperative Oncology Group performance 
status score of 0 or 1; adequate bone marrow, hepatic, and renal function; and measurable 
disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.17 Key 
exclusion criteria included previous therapy targeting T-cell costimulating or immune-checkpoint 
pathways; known HIV or hepatitis B or C virus infection; and active brain metastases, auto-
immune disease, or systemic immunosuppression. After initial eligibility was established and 
informed consent had been obtained, patients were enrolled into the study via an interactive 
voice response system. All patients provided written informed consent to participate based on 
the principles of the Declaration of Helsinki. The study was approved by the institutional review 
board or independent ethics committee at each centre and was done in accordance with Good 
Clinical Practice guidelines defined by the International Conference on Harmonisation. 
Nivolumab was provided by the sponsor (Bristol-Myers Squibb, Princeton, NJ, USA). 
On Jan 26, 2016, the independent data monitoring committee reviewed the data at the 
planned interim analysis and declared overall survival superiority for nivolumab over 
investigator’s choice therapy.16 The protocol was amended to allow patients in the investigator’s 
choice group to cross over to nivolumab. All patients not on active therapy are being followed for 
survival. 
 
Randomisation and masking 
Patients were randomly assigned (2:1) via an interactive voice response system to receive 
either nivolumab or investigator’s choice. Randomisation was stratified by previous cetuximab 
use. The study was open-label; patients and investigators were not masked to treatment 
allocation. 
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Procedures 
Patients received nivolumab 3 mg/kg as a 60 min intravenous infusion every 2 weeks, or 
investigator’s choice therapy, consisting of weekly intravenous administrations of methotrexate 
(40–60 mg/m² of body surface area), docetaxel (30–40 mg/m²), or cetuximab (250 mg/m² after a 
loading dose of 400 mg/m²) until disease progression, intolerable toxicity, or withdrawal of 
consent. However, nivolumab treatment could be continued beyond disease progression, as 
assessed clinically or radiographically, if the investigator determined that it was providing clinical 
benefit. 
Disease assessments were done with CT or MRI at baseline, and every 6 weeks 
beginning at week 9. Imaging data were assessed by the investigators to establish tumour 
response according to RECIST version 1.1. Toxicity was assessed according to Common 
Terminology Criteria for Adverse Events version 4.0 at each visit during the treatment phase 
and for 100 days after discontinuation. Patients were followed for overall survival every 3 
months until death, loss to follow-up, or withdrawal of consent. 
Formalin-fixed, paraffin-embedded tumour samples required for enrolment were centrally 
assessed for tumour-cell membrane expression of programmed death ligand 1 (PD-L1) by 
immunohistochemistry (Dako North America, Carpinteria, CA, USA) using a rabbit antihuman 
PD-L1 antibody (clone 28–8, Epitomics, Burlingame, CA, USA). Expression in a minimum of 
100 evaluable tumour cells was scored for PD-L1 (≥1% or <1% expression). 
Documentation of p16-positive or p16-negative disease to determine human 
papillomavirus (HPV) status of tumour was required for patients with oropharyngeal cancer. 
HPV p16 status was assessed by local or central laboratory immunohistochemical analysis. 
Samples were considered positive if more than 70% strong and diffuse nuclear and cytoplasmic 
staining specific to tumour cells was present. 
PRO assessments were done at baseline before treatment initiation, at week 9, and then 
every 6 weeks during the treatment period using three validated patient-reported 
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questionnaires:8,9,18–22 the 30-question cancer-specific European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 30 (QLQ-C30); the 35-
question head and neck cancer-specific EORTC Quality-of-Life Module for Head and Neck 
Cancer (QLQ-H&N35); and the three-level version of the European Quality of Life–5 
Dimensions (EQ-5D-3L) questionnaire. Post-treatment assessments were made at follow-up 
visits 1 and 2 (35 days give or take 7 days after the last treatment dose, and 80 days give or 
take 7 days after follow-up visit 1). The EQ-5D-3L questionnaire was also administered at 
survival follow-up visits (every 3 months give or take 7 days after follow-up visit 2). Patients 
completed their assessments at each timepoint before physician contact, treatment dosing, or 
any procedures. PRO measures were self-administered by paper and pencil during the on-
treatment phase and at follow-up visits 1 and 2. They were either self-administered by paper 
and pencil or completed via a telephone interview during survival follow-up. Specific information 
about reasons patients did not complete questionnaires were not collected, because this was 
not specified in the protocol. 
The EORTC QLQ-C30 questionnaire (version 3.0) consists of five functional scales 
(physical, role, social, emotional, and cognitive functioning), nine scales measuring symptoms 
or concerns relevant to patients with cancer (fatigue, nausea and vomiting, pain, dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), as well as one scale 
measuring global health and quality of life.23,24 For each functional and symptom question, 
patients responded to a 4-point categorical scale ranging from 1 (“not at all”) to 4 (“very much”); 
responses to the two items in the global health and quality-of-life scale were given on a 7-point 
Likert scale. Item responses were aggregated and linearly transformed to a 0–100 scale 
according to the EORTC scoring manual.25 From there, scales where higher scores represented 
higher symptom burden were reverse-scored to simplify presentation within this report so that 
for all scales a higher score represents better quality of life. 
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The EORTC QLQ-H&N35 questionnaire consists of seven multi-item symptom scales 
(pain, sensory problems, social contact problems, swallowing, social eating problems, speech 
problems, and reduced sexuality) and 11 single-item symptom scales (nutritional supplement 
use, mouth opening problems, teeth problems, coughing, painkiller use, weight loss, weight 
gain, sticky saliva, feeding tube, dry mouth, and feeling ill).26,27 Most items were rated on a 4-
point scale ranging from 1 (“not at all”) to 4 (“very much”); five components used a binary 
response set (“yes” or “no”). Patient responses were transformed to a 0–100 scale according to 
the EORTC scoring manual.25 From there, scales were reverse-scored to simplify presentation 
within this report so that for all scales a higher score represents better quality of life. 
The EQ-5D-3L is a standardised questionnaire commonly used to measure self-reports 
of health status and functioning.28,29 It consists of two components, a descriptive system and a 
visual analogue scale (VAS). The descriptive system covers five dimensions (mobility, self-care, 
usual activities, pain or discomfort, and anxiety or depression), each of which is rated on a 
three-level scale (corresponding roughly to no problems, moderate problems, or extreme 
problems), resulting in a five-digit vector that describes a patient’s health state—eg, vectors 
11111 and 33333 represent the best and worst health states possible, respectively. EQ-5D 
responses were weighted and aggregated using the UK preference-weighting algorithm30 to 
produce utility scores measuring the value of a respondent’s health state to society, where a 
score of 0 was equivalent to being dead and 1 was equivalent to full health. The VAS is a 
vertical scale from 0 (worst imaginable) to 100 (best imaginable), on which patients were asked 
to report their overall health status on that day. 
 
Outcomes 
The primary endpoint of CheckMate 141 was overall survival, defined as time from 
randomisation to the date of death, reported previously.16 Secondary endpoints were 
investigator-assessed progression-free survival and the proportion of participants who achieved 
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an objective response per RECIST version 1.1. PRO analyses were exploratory endpoints. PRO 
endpoints were interpreted based upon both significant differences and clinically meaningful 
differences. Statistical differences in PRO endpoints included evaluation of adjusted mean 
changes from baseline between treatment groups as assessed by the EORTC QLQ-C30, 
EORTC QLQ-H&N35, and EQ-5D-3L at each timepoint, and the time to clinically meaningful 
deterioration per each individual scale’s criteria. 
The clinically meaningful difference, indicating a change that would be detectable by 
patients and might mandate a change in the patient’s management, was a score difference of 
10 points or more for all domains on both EORTC questionnaires.31 Interpretation for the 
EORTC QLQ-C30 was also prespecified based on newer subscale-specific guidelines, where 
clinically meaningful score differences vary by domain.32,33 A change from baseline of 10 points 
was also used as a clinically important deterioration within an individual for the time to 
deterioration analyses for all domains on both EORTC questionnaires. Score differences of 0·08 
or more for the EQ-5D utility index and 7 or more for the EQ-5D VAS have been determined to 
be clinically relevant and were used as the clinically meaningful difference for these measures.22 
 
Statistical analyses 
The statistical analysis of the exploratory PRO endpoint were predefined in a PRO statistical 
analysis plan. Assessments were considered complete if at least half of the questions were 
completed or answered. Completion rates were calculated for each PRO measure as the 
proportion of patients alive in the study at the assessment timepoint with a completed 
questionnaire. To investigate the relation of PRO scores with dropout, patients were grouped 
according to the timing of their last assessment and mean PRO scores plotted over time for 
each group by treatment group. Patients with dropout after 21 weeks were combined because 
of small sample sizes. 
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Quality of life results within and between treatment groups were assessed using 
descriptive statistics and ANCOVA, adjusted for the stratified randomisation (previous 
cetuximab therapy) and baseline score, at each timepoint when sample size was 10 or more. 
The ANCOVA model treated change from baseline as the dependent variable and treatment 
and visit as fixed effects, with visits as a repeated measure. A separate analysis was done for 
each domain, and only patients with questionnaires completed at baseline and at least one 
post-baseline assessment were included in the analysis. Missing data were not imputed. 
p values reported are for parametric tests with significance testing at the 0·05 level, with 
no adjustment for multiplicity. Interaction p values are used to assess whether the treatment 
effect varied across the prespecified subgroups (eg, baseline PD-L1 expression [<1% or ≥1%]). 
Median time from randomisation to first deterioration (defined based on clinically 
meaningful change) was estimated by the Kaplan-Meier method, and two-sided 95% CIs were 
computed using a generalisation of the Brookmeyer and Crowley method (log-log 
transformation). Deterioration was applied at the individual patient level; confirmation was not 
required at a subsequent visit; progression or death were not included as events or censored. A 
Cox proportional hazard regression model was used to estimate relative risk for the time to 
deterioration, treating baseline score and previous cetuximab therapy as covariates. Hazard 
ratios (HRs) were calculated for the risk of deterioration in the nivolumab group over the 
investigator’s choice group, with ratios less than 1 representing decreased likelihood of 
experiencing deterioration in the nivolumab group. All randomised patients were included in the 
time-to-deterioration analyses; these analyses include data collected at all available timepoints, 
including post-treatment follow-up. Patients with no baseline PRO data were censored to day 1; 
patients with baseline but no additional post-baseline data were censored to day 2.34 This 
censoring was necessary because Cox hazard ratio estimates can only be calculated on cases 
with non-missing baseline covariates. 
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The data cutoff point for the analyses of overall survival, progression-free survival, and 
safety was Dec 18, 2015 (planned interim analysis). Response and PRO data were based on a 
May 5, 2016, database lock. 
Data were analysed with SAS (version 9.4, SAS Institute, Cary, NC, USA). 
This trial is registered with ClinicalTrials.gov, number NCT02105636. 
 
Role of the funding source 
The funders contributed to the study design, and the collection, analysis, and interpretation of 
the data in collaboration with the investigators and authors of this report. Funds for editorial and 
writing support were provided by the funder. All authors had full access to the raw data. The 




Between May 29, 2014, and July 31, 2015, patients were enrolled, and subsequently 361 
patients were randomly assigned to receive nivolumab (n=240) or investigator’s choice (n=121). 
Median follow-up for analysis was 4·6 months (IQR 2·3–6·2). At baseline, 74–80% of patients 
completed PRO questionnaires (appendix p 3). However, completion rates decreased over time 
and diminishing sample size for the investigator’s choice group (n<10) precluded the 
performance of ANCOVA analyses of treatment-related differences beyond 15 weeks. Thus, 
129 patients (93 in the nivolumab group and 36 in the investigator’s choice group) who 
completed any of the PRO questionnaires at baseline and at least one other assessment were 
included in change from baseline analyses. Baseline characteristics were similar between 
treatment groups within this subset of patients (appendix p 4). 
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Mean graphs by the timing of last assessment showed that patients with only a baseline 
assessment (41·7–45·4% of the randomised sample) generally had lower functioning and 
higher symptoms compared with patients who provided PRO assessments at follow-up 
timepoints. EORTC QLQ-C30 and EORTC QLQ-H&N35 scores in the nivolumab group were 
generally stable before dropout, whereas in the investigator’s choice group, patients were either 
stable or declining before dropout. No clear trends in the EQ-5D data were noted for either 
treatment group before dropout (data not shown). 
Mean scores for all individual domains on the EORTC QLQ-C30 were similar between 
groups at baseline for the analytical cohort (n=127; 91 in the nivolumab group and 36 in the 
investigator’s choice group; appendix pp 5, 6), with the exception of financial difficulties 
(nivolumab, 18·9 [SD 24·5]; investigator’s choice, 31·5 [36·5]; appendix pp 5, 6), and for the all-
randomised population (see supplementary table 7 in Ferris et al16). Treatment with nivolumab 
resulted in adjusted mean changes from baseline to weeks 9 and 15 ranging from −2·1 to 5·4 
across functional and symptom domains measured by the EORTC QLQ-C30, indicating no 
clinically meaningful changes. By contrast, clinically meaningful deterioration occurred in eight 
(53%) of the 15 domains in the investigator’s choice group at week 15 (decline of 10 points or 
more; appendix pp 5, 6), with adjusted mean changes from baseline to weeks 9 and 15 ranging 
from −24·5 to 2·4. Examples shown in figure 1A are adjusted least squares mean changes from 
baseline for fatigue, dyspnoea, and appetite loss. Clinically meaningful improvement or 
deterioration by newer guidelines32,33 is indicated in the appendix (pp 5, 6). 
At both weeks 9 and 15, adjusted mean differences between groups were significant and 
clinically meaningful (according to a difference of 10 points or greater) in favour of nivolumab for 
role functioning, social functioning, fatigue, dyspnoea, and appetite loss (figure 1B). Additional 
significant and clinically meaningful differences favouring nivolumab were noted at either week 9 
(diarrhoea) or week 15 (physical functioning, cognitive functioning, and insomnia). Further 
domains that were either significant or clinically meaningful are shown in figure 1B. No 
CheckMate 141 PRO  Harrington et al. 
 
Page 16 of 49 
 
significant or clinically meaningful differences were noted in favour of investigator’s choice on 
the EORTC QLQ-C30. 
In exploratory analyses, we assessed changes from baseline in EORTC QLQ-C30 
scores among patients whose tumours had 1% or more or less than 1% PD-L1 expression 
(appendix p 7) or were p16-positive or p16-negative (appendix p 8). Adjusted mean differences 
between treatment groups were in line with the overall treatment effect for each domain, 
suggesting no evidence of a differential benefit across these subgroups. 
Nivolumab significantly delayed the time to deterioration compared with investigator’s 
choice for global health status; physical, role, cognitive, and social functioning; and symptoms of 
fatigue, dyspnoea, insomnia, and appetite loss on the EORTC QLQ-C30 (figure 2; appendix p 
9). Nivolumab treatment more than doubled the Kaplan-Meier estimate of the median time to 
first clinically meaningful deterioration compared with investigator’s choice for physical and 
social functioning, pain, dyspnoea, and insomnia (figure 2B). 
Quality-of-life outcomes as measured by the head and neck cancer-specific EORTC 
QLQ-H&N35 were consistent with the results of the EORTC QLQ-C30 analysis. At baseline, 
mean scores for individual domains were similar between groups for the analytical cohort 
(n=128; appendix pp 5, 6), with the exceptions of social eating problems, teeth problems, dry 
mouth, and painkiller use, and for the all-randomised population (see supplementary table 7 in 
Ferris et al16). Treatment with nivolumab resulted in adjusted mean changes from baseline to 
weeks 9 and 15 ranging from −4·1 to 15·3 across EORTC QLQ-H&N35 domains (figure 3A; 
appendix pp 5, 6). Changes from baseline in weight gain in the nivolumab group were −13·2 at 
week 9 and −15·2 at week 15, indicating that patients experienced an increase in weight at 
these timepoints. By contrast, treatment with investigator’s choice led to clinically meaningful 
deterioration (decline of 10 points or more) at week 15 for sensory problems, social eating 
problems, social contact problems, mouth opening problems, sticky saliva, feeling ill, painkiller 
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use, and weight loss (appendix pp 5, 6). The adjusted mean changes from baseline to weeks 9 
and 15 for the investigator’s choice group ranged from −26·8 to 13·4. 
At weeks 9 and 15, adjusted mean differences between groups were significant and 
clinically meaningful (according to a difference of 10 points or greater) in favour of nivolumab for 
pain and sensory problems (figure 3B). Additional significant and clinically meaningful 
differences favouring nivolumab were noted at either week 9 (nutritional supplement use) or 
week 15 (social contact problems, mouth opening problems, sticky saliva, feeling ill, painkiller 
use, and weight loss). Further domains that were either significant or clinically meaningful are 
shown in figure 3B. Patients treated with nivolumab experienced more weight gain (difference 
not significant) and significantly less weight loss compared with investigator’s choice. The trends 
observed for the change from baseline as measured by the EORTC QLQ-H&N35 were similar 
to the overall treatment effect regardless of PD-L1 expression (<1% or ≥1%; appendix p 10) or 
p16 status (appendix p 11) for each domain. 
Median time to deterioration was significantly delayed by treatment with nivolumab 
compared with investigator’s choice on the EORTC QLQ-H&N35 for pain, sensory problems, 
social contact problems, and mouth opening problems (appendix p 12–14). Median time to 
clinically meaningful increase in weight was reached in the nivolumab group, but not in the 
investigator’s choice group. 
The EQ-5D VAS, a measure of the patient’s overall health status, was similar between 
groups at baseline for the analytical cohort (n=124; appendix pp 5, 6) and all-randomised 
population (see supplementary table 7 in Ferris et al16). However, patients in the nivolumab 
group had a clinically meaningful improvement (according to a difference of 7 points or greater) 
in adjusted mean change in VAS score from baseline to week 15, by contrast with a clinically 
meaningful deterioration in the investigator’s choice group (7·3 vs –7·8; appendix pp 5, 6). 
Notably, the difference between groups at week 15 was both significant and clinically 
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meaningful in favour of nivolumab (figure 4A). Median time to deterioration on the EQ-5D VAS 
was not significantly different (figure 4B, 4C). 
Baseline utility index score, a composite score representing the value placed by society 
on a respondent’s current health state as defined based on the attributes measured by the EQ-
5D, was similar in the two treatment groups (appendix pp 5, 6). Neither significant nor clinically 
meaningful differences in outcomes were observed at 9 or 15 weeks within or between groups 
(figure 4A). Median time to deterioration on the EQ-5D utility index was not significant (figure 
4B, 4C). Median time to deterioration was significantly longer with nivolumab versus 
investigator’s choice for 13 (37%) of 35 domains assessed across the three questionnaires. 
 
Discussion 
Here we report that nivolumab stabilised several measures of quality of life during the 
first 15 weeks of treatment of patients with platinum-refractory recurrent or metastatic squamous 
cell carcinoma of the head and neck, and delayed time to deterioration compared with single-
agent therapy of investigator’s choice based on an exploratory analysis from CheckMate 141, a 
randomised, phase 3 trial. The clinical benefit, as measured by these validated PRO measures, 
indicates that patients experienced improved quality of life in addition to prolonged survival, 
higher response rate, and fewer high-grade toxicities relative to investigator’s choice.16 These 
results are consistent with studies of nivolumab in melanoma, non-small-cell lung cancer, and 
renal cell carcinoma, which showed stable or improved quality of life with nivolumab compared 
with dacarbazine, docetaxel, and everolimus, respectively.35–38 
Maximising the quality of life of patients with cancer is increasingly recognised as an 
important therapeutic goal,1,10 particularly in the context of improved survival. Patients with 
squamous cell carcinoma of the head and neck rank the ability to speak, swallow, and perform 
daily tasks in the absence of pain as very high priorities.39,40 Patients with recurrent or 
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metastatic squamous cell carcinoma of the head and neck face a dismal prognosis with poor 
quality of life, including more severe social and psychological problems than those with other 
cancers.1 Both the disease and its treatments can have a major effect on facial structures, 
causing anatomical and functional defects. Patients with recurrent or metastatic squamous cell 
carcinoma of the head and neck might have residual toxicities caused by previous systemic 
therapies that can affect performance status, restrict the administration of subsequent 
treatments, and predispose patients to developing additional toxicities.10 
The results presented here interpret a larger positive difference in change (nivolumab 
minus investigator’s choice) as better, for all domains. This confounds the interpretation of 
changes in weight, because all symptom domains, including weight gain and weight loss, were 
scored in the same direction. At week 15, our results showed a positive difference for weight 
loss (interpreted as favouring nivolumab) but a negative difference for weight gain (interpreted 
as favouring investigator’s choice) as a result of scoring algorithms applied to the weight loss 
and weight gain domains. In fact, nivolumab was associated with less weight loss and more 
weight gain than investigator’s choice. In view that 35–50% of patients with squamous cell 
carcinoma of the head and neck experience weight loss41 and often have difficulties eating, 
weight gain can be viewed as a positive effect in this population. Together, results for weight 
loss and weight gain suggest that, at 15 weeks, patients treated with nivolumab exhibited a 
more desirable trajectory in weight than did those treated with investigator’s choice. 
In our analyses, the endpoint predefined in the statistical analysis plan was time to 
quality-of-life deterioration, which does not include death as an event. No consensus exists on 
the best definition to use for time to deterioration analyses; however, our analysis followed 
current recommendations.34 Importantly, the threshold used to determine clinical relevance on 
the EORTC QLQ-C30 (10 points) is based on observations in other cancers. Based on a recent 
meta-analysis from Cocks and colleagues32,33 consisting of multiple cancers and a variety of 
clinical situations, clinically meaningful differences might in fact be seen at even lower 
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thresholds. Therefore, the use of a 10-point difference in our manuscript is probably a 
conservative estimate of within and between-treatment group differences. With the newer 
guidelines, additional domains showed improvement with nivolumab or deterioration with 
investigator’s choice, indicating that the overall clinical benefit of nivolumab might be even 
greater. 
To our knowledge, this is the first comprehensive report on PROs for an immunotherapy 
agent in squamous cell carcinoma of the head and neck. Furthermore, few studies have 
reported on the quality of life, symptom burden, or functioning in patients with recurrent or 
metastatic squamous cell carcinoma of the head and neck.1,7,10 In the EXTREME study,8 where 
patients received platinum-fluorouracil alone or in combination with cetuximab as first-line 
therapy for recurrent or metastatic squamous cell carcinoma of the head and neck, few domains 
on the EORTC QLQ-C30 and EORTC QLQ-H&N35 were reported. The results showed that at 
cycle 3 and month 6, quality of life was not significantly worse with the addition of cetuximab. At 
cycle 3, pain, swallowing, speech problems, and social eating problems significantly favoured 
the cetuximab group on the QLQ-H&N35, whereas improvements on the QLQ-C30 were not 
significant after adjustment for baseline score. In the platinum-refractory setting, a study of 
afatinib versus methotrexate showed an improvement in pain on the EORTC QLQ-H&N35 with 
afatinib versus methotrexate, but no differences in swallowing or global health status.9 Median 
time to deterioration was statistically longer with afatinib for these measures, but medians 
ranged from 2·1 months to 2·7 months for methotrexate and from 3·0 months to 3·8 months for 
afatinib. Whereas previous trials have shown limited quality-of-life effects on only a few 
outcomes, results presented here show consistency across several questionnaires and a large 
number of relevant outcomes. Patients benefitted from nivolumab regardless of both PD-L1 and 
p16 status. 
Although the questionnaires used in this trial have been used previously in several 
clinical trials, their validation has been done primarily in patients with locally advanced 
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disease;10 thus, it is possible that certain symptoms of importance in recurrent or metastatic 
squamous cell carcinoma of the head and neck could have been missed in this and other trials. 
Furthermore, the EQ-5D is a measure that can be used in general or targeted clinical 
populations, and is not apt to be as sensitive as a condition-targeted measure that is used in the 
designated population. However, the EQ-5D includes other measures that are important to 
patients with squamous cell carcinoma of the head and neck such as anxiety and depression, 
as well as measures not covered by the EORTC measures such as the ability to do general, 
daily activities. 
No adjustment for multiple testing for exploratory endpoints is a common and widely 
accepted statistical practice. However, this could also be a limitation of the study in that an 
absence of alpha hierarchy and failing to adjust for multiplicity could have some implications for 
inferences that are close to the 0·05 benchmark. As is common with PROs,8,10,19 our analysis 
was also limited by relatively low completion rates. After week 15, numbers in the investigator’s 
choice group were so few as to preclude statistical comparisons between groups. Questionnaire 
response rates typically correspond to patient morbidity and functional status; patients affected 
by physical and psychological factors such as fatigue and depression might be unable to 
complete the assessments, depending on the response format, delivery, and length of the 
questionnaire.1,7,42 One possible explanation for the higher level of missing data in the 
investigator’s choice group is the potential bias of an open-label study, where the patient’s 
excitement about the investigational agent might lead to more enthusiastic participation, 
including completion of questionnaires or ranking the agent positively. To explore the effect of 
patients being aware of their treatment allocation, baseline quality-of-life scores were compared 
across groups to determine whether there was a consistent bias. Across the 15 EORTC QLQ-
C30 domains and 18 EORTC QLQ-H&N35 domains, only five domains had differences across 
the groups—worse financial difficulties, social eating, teeth problems, and dry mouth in the 
investigator’s choice group, and increased painkiller use in the nivolumab group. Some of these 
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differences might be expected by chance across this large number of domains, and this does 
not seem to imply a consistent bias in the quality-of-life responses towards the nivolumab group. 
Baseline scores were accounted for in the ANCOVA analyses. This might also have been 
affected by differential progression or the higher number of patients experiencing prolonged 
disease control in the nivolumab group, whereby patients could have maintained the ability to 
respond to their questionnaires, as well as maintaining their quality of life. Another possible 
explanation is the known acute toxicity associated with therapies used in the investigator’s 
choice group. Similar attrition has been noted in previous studies in patients with squamous cell 
carcinoma of the head and neck, with those discontinuing generally representing patients with 
the worst quality of life,8,20,43 and presenting a significant challenge for statistical analyses. For 
example, during the EXTREME trial,8 only 44% of patients had both an evaluable baseline and 
a post-baseline assessment. The nature of the missing data was investigated to understand the 
effect on results presented. The analysis population was similar to the full study population in 
terms of most demographics and disease characteristics. Generally, patients with only a 
baseline assessment had lower functioning and worse symptom scores than those providing 
further quality-of-life assessments. Before dropout, EORTC domain scores were stable in the 
nivolumab group but declined in the investigator’s choice group. This would suggest that our 
estimates of treatment differences are likely to be conservative. 
The results of CheckMate 141 suggest that nivolumab is the first PD-1 inhibitor, to our 
knowledge, to show a significant improvement in overall survival, with better tolerability and a 
quality-of-life benefit, compared with standard therapy for platinum-refractory recurrent or 
metastatic squamous cell carcinoma of the head and neck. In view of the major unmet need in 
this population and the importance of maintaining or improving quality of life for patients with 
recurrent or metastatic squamous cell carcinoma of the head and neck, these data support 
nivolumab as a new standard of care option in this setting. 
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Figure 1: EORTC QLQ-C30 ANCOVA analyses  
 
Adjusted mean change from baseline in fatigue, dyspnoea, and appetite loss at weeks 9 and 15 
(A) and least square (LS) mean difference between treatment groups (B). Dashed lines indicate 
clinically meaningful change (10 points). The number of evaluable patients for each timepoint, 
domain, and treatment group can be found in the appendix (p 5). EORTC QLQ-C30=European 
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Figure 2: Kaplan-Meier plots of time to first clinically meaningful deterioration (A) and 
Kaplan-Meier estimate of median time to deterioration and HR (95% CI) for the EORTC 
QLQ-C30 (B) among all randomised patients 
The number of evaluable patients for each timepoint, domain, and treatment group in A can be 
found in the appendix (p 5). EORTC QLQ-C30=European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire–Core 30. HR=hazard ratio. NE=not 
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Figure 3: EORTC QLQ-H&N35 ANCOVA 
Adjusted mean (95% CI) change from baseline in mouth opening problems, sticky saliva, and 
feeling ill at weeks 9 and 15 (A) and adjusted least squares (LS) mean difference between 
treatment groups (B). Dashed lines indicate clinically meaningful change (10 points). The 
number of evaluable patients for each timepoint, domain, and treatment group can be found in 
the appendix (p 5). EORTC QLQ-H&N35=European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire head and neck cancer-specific module. *A negative 
value indicates an increase in weight gain.  
  
CheckMate 141 PRO  Harrington et al. 
 
Page 34 of 49 
 
Figure 4: EQ-5D-3L adjusted LS mean difference (95% CI) between nivolumab and 
investigator’s choice at weeks 9 and 15 (A); and time to deterioration (Kaplan-Meier plot 
of time to first clinically meaningful deterioration [B]) and Kaplan-Meier estimate of 
median time to deterioration and HR (95% CI) (C) 
 
Dashed lines in A indicate clinically meaningful change (0·08 points and 7 points for the utility 
index and VAS, respectively). EQ-5D-3L=three-level European Quality of Life–5 Dimensions 
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Table S1: Enrolment by country and site 
Country Principal investigator Institution Patients 
Treated, n 
USA George Blumenschein, Jr University of Texas MD Anderson 36 
United Kingdom Kevin J. Harrington Royal Marsden NHS Foundation Trust, Royal Marsden Hospital 23 
France Jerome Fayette Centre Leon Berard 20 
France Joel Guigay Centre Antoine Lacassagne 19 
USA A. Dimitrios Colevas Stanford University Medical Center 19 
Italy Lisa Licitra IRCCS Istituto Nazionale Tumori 18 
Germany Stefan Kasper University Hospital Essen 14 
USA Everett E. Vokes University of Chicago 14 
France Caroline Even Institut Gustave Roussy 13 
USA Maura L. Gillison The Ohio State University 13 
USA Francis Worden University of Michigan 13 
USA Nabil F. Saba Winship Cancer Institute 10 
Spain Lara Carmen Iglesias Docampo Hospital Universitario 12 De Octubre 8 
USA Robert Haddad Dana-Farber Cancer Institute 8 
Japan Naomi Kiyota Kobe University Hospital 7 
Switzerland Tamara Rordorf Universitatsspital Zurich 7 
USA Robert L. Ferris UPMC Cancer Center 7 
United Kingdom Shanmugasundaram Ramkumar Southampton University Hospital NHS Trust 6 
Spain Neus Baste Vall d’Hebron University Hospital 6 
Canada Cheryl Ho British Columbia Cancer Agency-Vancouver Centre 6 
USA Jeffery Russell H. Lee Moffitt Cancer Center 5 
Germany Peter Brossart Universitaetsklinikum Bonn 5 
Germany Rainald Knecht Uniklinikum Hamburg-Eppendorf 5 
Japan Makoto Tahara National Cancer Center Hospital East 5 
USA Kenneth Grossmann Huntsman Cancer Institute 5 
USA Frank Dunphy Duke University Medical Center  5 
Japan Yasuhisa Hasegawa Aichi Cancer Center Central Hospital 4 
Japan Shunji Takahashi Cancer Institute Hospital 4 
Spain Juan Jose Grau Hospital Clínic de Barcelona 4 
The Netherlands Jan Buter Vu Medisch Centrum 4 
The Netherlands S. J. Oosting Universitair Medisch Centrum Groningen 3 
United Kingdom Andrew Sykes Christie Hospital 3 
Argentina Mirta Susana Varela Centro de Oncología e Investigación de Buenos Aires 3 
Taiwan Chia-Jui Yen National Cheng Kung University Hospital 3 
Italy Mario Airoldi Azienda Ospedaliera Citta della Salute e della Scienza 2 
USA Thomas Cosgriff Crescent City Research Consortium, LLC 2 
Germany Viktor Gruenwald Med Hochschule Hannover 2 
Taiwan Ruey-Long Hong National Taiwan University Hospital 2 
United Kingdom David Husband Clatterbridge Hospital 2 
Italy Franco Ionna Istituto Nazionale Tumori Fondazione Pascale 2 
Japan Shigemichi Iwae Hyogo Cancer Center 2 
Japan Yasushi Shimizu Hokkaido University Hospital 2 
Japan Tomoya Yokota Shizuoka Cancer Center 2 
Italy Haralabos Koussis Istituto Oncologico Veneto IOV - IRCCS 2 
Brazil Carlos Henrique Barrios Hospital São Lucas da PUCRS 2 
Italy Daris Ferrari Azienda Ospedaliera San Paolo 1 
USA Jill Gilbert Vanderbilt Cancer Clinic 1 
Japan Masahiro Goto Osaka Medical College Hospital 1 
Republic of Korea Jin-Hyoung Kang The Catholic University of Korea, Seoul St. Mary's Hospital 1 
Germany Ulrich Keilholz Charité Universitätsmedizin Berlin 1 
Hong Kong Wing Sum Kenneth Li Queen Elizabeth Hospital 1 
Argentina Martin Eduardo Richardet Instituto Oncologico De Cordoba 1 
Germany Urs Mueller-Richter Klinikum der Universitaet Würzburg 1 
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Table S2: Completion rates for patient-reported outcome measures 
Pro measure/ 
Week  
NIVOLUMAB INVESTIGATOR’S CHOICE 
Forms received 
Patients 
on study Completed (%) Forms received 
Patients 
on study Completed (%) 
EORTC QLQ-C30 
0 191 240 79·6 91 121 75·2 
9 105 131 80·2 34 57 59·7 
15 58 85 68·2 16 30 53·3 
21 48 58 82·8 7 14 50·0 
27 31 44 70·5 2 5 40·0 
33 21 30 70·0 3 3 100·0 
39 10 19 52·6 1 1 100·0 
45 11 15 73·3 0 0 NA 
51 6 9 66·7 0 0 NA 
57 3 5 60·0 0 0 NA 
69 2 2 100·0 0 0 NA 
EORTC QLQ-H&N35 
0 193 240 80·4 91 121 75·2 
9 104 131 79·4 36 56* 64·3 
15 58 85 68·2 15 30 50·0 
21 47 58 81·0 7 14 50·0 
27 31 44 70·5 2 5 40·0 
33 21 30 70·0 3 3 100·0 
39 9 19 47·4 1 1 100·0 
45 11 15 73·3 0 0 NA 
51 6 9 66·7 0 0 NA 
57 3 5 60·0 0 0 NA 
69 1 1 100·0 0 0 NA 
EQ-5D-3L 
0 191 240 79·6 90 121 74·4 
9 103 131 78·6 35 57 61·4 
15 58 85 68·2 16 30 53·3 
21 48 58 82·8 7 14 50·0 
27 31 44 70·5 2 5 40·0 
33 21 30 70·0 2 3 66·7 
39 9 19 47·4 1 1 100·0 
45 11 15 73·3 0 0 NA 
51 6 9 66·7 0 0 NA 
57 3 5 60·0 0 0 NA 
69 2 2 100·0 0 0 NA 
*One patient in the investigator’s choice arm met eligibility criteria for completing the EORTC QLQ-C30 but not 
the QLQ-H&N35 at week 9. Accordingly, the number of on-study patients in the investigator’s choice arm is listed 
as being different for the 2 measures. EORTC QLQ-C30=European Organisation for the Research and Treatment of 
Cancer Quality of Life Questionnaire–Core 30. EORTC QLQ-H&N35=European Organisation for the Research and 
Treatment of Cancer Quality of Life Questionnaire head and neck cancer–specific module. EQ-5D-3L=three-level 
European Quality of Life–5 Dimensions questionnaire; NA=not applicable; PRO=patient-reported outcome. 
From The New England Journal of Medicine, Ferris RL, et al., Nivolumab for Recurrent Squamous-Cell Carcinoma 
of the Head and Neck, 375, 1856–1867. Copyright © 2016 Massachusetts Medical Society. Reprinted with 
permission from Massachusetts Medical Society. 
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Table S3: Baseline characteristics among patients included in ANCOVA analyses 
Characteristic Nivolumab (n=93) Investigator's choice (n=36) 
Age, median (range), years 
























































Smoking or tobacco use, n (%) 











Prior cetuximab treatment, n (%) 52 (55·9) 20 (55·6) 
*
 
Based on available data (n=89). ANCOVA=analysis of covariance. ECOG=Eastern Cooperative Oncology Group. 
PD-L1=programmed death ligand 1. 
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Baseline* Week 9 Week 15 
Nivolumab Investigator’s choice Nivolumab Investigator’s choice Nivolumab Investigator’s choice 
EORTC QLQ-C30†  
(n = 127) n Mean (SD) n Mean (SD) n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change 
Global health status 89 60·3 (21·4) 36 61·8 (18·7) 83 2·4 (4·1) 30 −5·8 (6·7)‡ 44 2·7 (5·3) 13 −7·3 (10·0)‡ 
Physical functioning 89 81·0 (18·5) 36 76·7 (24·5) 84 1·3 (2·9) 30 −6·0 (4·9)‡ 43 −1·9 (3·9) 14 −19·9 (6·9)§ 
Role functioning 88 76·1 (27·2) 36 69·0 (33·4) 83 4·9 (4·9) 29 −9·7 (8·2)‡ 42 −0·3 (5·9) 14 −23·8 (10·4)§ 
Emotional functioning 90 80·2 (18·7) 36 81·3 (18·6) 84 1·0 (3·5) 30 −7·2 (5·7)‡ 44 −1·9 (4·3) 13 −9·9 (8·0)‡ 
Cognitive functioning 90 87·0 (18·8) 36 90·3 (14·0) 84 1·8 (3·5) 30 −4·9 (5·7)‡ 44 −1·3 (4·5)‡ 13 −16·0 (8·2)ǁ 
Social functioning 89 73·6 (28·8) 36 76·9 (29·9) 83 5·3 (4·5)¶ 30 −8·5 (7·2)‡ 44 5·4 (5·5)¶ 13 −15·8 (10·2)ǁ 
Fatigue 89 32·4 (23·7) 36 34·9 (21·6) 84 4·1 (4·1) 30 −6·6 (6·7)‡ 43 1·1 (4·9) 14 −21·8 (8·6)§ 
Nausea and vomiting 89 6·0 (11·0) 36 7·4 (13·5) 84 0·2 (3·3) 30 −3·9 (5·5) 43 −2·1 (4·5) 14 −9·9 (8·0)‡ 
Pain 91 31·3 (27·3) 36 29·2 (29·1) 86 4·0 (4·9) 30 2·2 (8·0) 44 2·6 (6·3) 14 −9·8 (11·4)‡ 
Dyspnoea 89 17·2 (24·2) 36 18·5 (25·8) 83 3·0 (4·3)¶ 30 −7·5 (7·2)‡ 43 1·5 (5·9) 14 −23·7 (10·4)ǁ 
Insomnia 89 22·5 (27·4) 36 24·1 (28·3) 83 2·2 (5·1) 30 −4·1 (8·4)‡ 43 4·4 (6·5) 14 −24·5 (11·6)§ 
Appetite loss 89 22·8 (29·6) 36 31·5 (36·5) 84 2·1 (5·9) 30 −10·1 (9·8)‡ 43 2·2 (7·6) 14 −20·9 (13·5)ǁ 
Constipation 90 18·1 (26·5) 36 25·9 (33·0) 84 5·3 (4·9)¶ 30 −2·9 (8·0) 44 3·4 (5·9) 13 2·4 (10·6) 
Diarrhoea 90 7·4 (19·8) 36 4·6 (11·7) 84 1·6 (3·3) 30 −9·3 (5·3)‡ 44 1·2 (4·1) 13 −5·9 (7·8)‡ 
Financial difficulties 90 18·9 (24·5) 36 31·5 (36·5) 84 1·1 (4·7) 29 1·2 (8·0) 44 0 (5·7) 13 −3·7 (10·6)‡ 
EORTC QLQ-H&N35† 
(n = 128) n Mean (SD) n Mean (SD) n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change 
Pain 92 23·4 (23·9) 36 24·8 (28·6) 85 4·4 (3·7) 30 −12·6 (6·3) 46 5·0 (4·7) 14 −6·7 (8·6) 
Swallowing problems 92 26·1 (27·5) 35 24·5 (21·9) 83 0·1 (4·3) 29 −5·5 (7·2) 46 −3·2 (5·1) 13 −5·1 (9·2) 
Sensory problems 91 25·1 (27·9) 36 23·1 (26·8) 84 4·4 (4·5) 29 −7·3 (7·6) 45 3·7 (5·5) 14 −18·2 (10·0) 
Speech problems 88 30·3 (26·4) 35 27·9 (30·7) 80 0·8 (4·3) 28 2·4 (7·0) 44 2·1 (5·3) 14 0 (9·4) 
Social eating problems 89 26·4 (29·2) 35 38·8 (27·6) 79 0·6 (4·7) 28 −1·6 (7·8) 45 −1·0 (5·5) 14 −11·5 (9·8) 
Social contact problems 89 16·1 (22·7) 36 15·9 (19·8) 81 1·2 (3·7) 29 −3·0 (6·1) 45 1·8 (4·5) 14 −13·7 (7·8) 
Less sexuality 87 44·3 (38·3) 35 42·4 (40·3) 80 −0·1 (6·7) 29 3·0 (11·0) 42 4·5 (8·2) 13 1·4 (14·9) 
Teeth problems 89 16·9 (28·9) 36 26·9 (37·2) 82 0·8 (5·3) 29 −0·6 (8·8) 45 1·9 (5·9) 13 0 (12·2) 
Mouth opening problems 92 34·4 (38·1) 36 38·9 (36·9) 83 1·5 (5·5) 30 −1·7 (9·2) 46 5·6 (6·7) 14 −11·0 (12·2) 
Dry mouth 92 38·4 (36·0) 36 54·6 (35·8) 85 −0·8 (5·7) 30 −1·8 (9·6) 46 9·3 (7·2) 14 −0·2 (13·3) 
Sticky saliva 91 35·5 (34·7) 36 38·0 (34·9) 84 −2·9 (6·3) 29 −12·5 (10·4) 45 2·9 (7·8) 14 −21·1 (14·1) 
Coughing 92 29·7 (29·4) 36 32·4 (30·3) 85 0·8 (5·5) 30 −6·8 (9·2) 46 4·6 (7·2) 14 −8·3 (13·1) 
Feeling ill 92 21·0 (26·9) 36 18·5 (29·2) 85 4·0 (4·9) 30 −3·5 (8·2) 46 5·9 (6·5) 14 −25·0 (11·8) 
Painkiller use 90 72·2 (45·0) 36 61·1 (49·4) 83 10·6 (8·8) 29 13·4 (14·5) 45 13·8 (10·8) 14 −12·5 (19·4) 
Nutritional supplement use 89 43·8 (49·9) 36 47·2 (50·6) 82 0·8 (9·2) 29 −21·6 (15·5) 44 −4·1 (12·0) 14 −5·6 (21·4) 
Feeding tube 90 27·8 (45·0) 36 22·2 (42·2) 83 0·2 (6·3) 29 3·0 (10·2) 45 −1·9 (6·5) 14 3·9 (11·0) 
Weight loss 89 36·0 (48·3) 36 33·3 (47·8) 82 5·0 (9·6) 29 −6·1 (16·1) 44 15·3 (12·3) 14 −26·8 (22·1) 
Weight gain# 89 21·3 (41·2) 36 25·0 (43·9) 81 −13·2 (9·8) 29 −12·8 (16·5) 41 −15·2 (12·7) 13 0·8 (22·9) 
EQ-5D-3L  
(n = 124) n Mean (SD) n Mean (SD) n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change n 
LS mean  
(95% CI) change 
Utility index 87 0·69 (0·28) 33 0·65 (0·27) 81 0·06 (0·04) 27 0·03 (0·07) 42 0·05 (0·06) 14 −0·03 (0·10) 
VAS 89 55·8 (28·0) 33 62·6 (28·2) 83 3·6 (4·9) 27 −2·4 (8·6) 44 7·3 (6·7) 13 −7·8 (12·3) 
Italic typeface indicates clinically meaningful difference between arms in baseline score and bold typeface indicates clinically meaningful change from baseline 
(≥10 points for the EORTC domains, ≥0·08 points for the EQ-5D utility index, and ≥7 points for the EQ-5D VAS). CI=confidence interval. EORTC QLQ-
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C30=European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire–Core 30. EORTC QLQ-H&N35=European Organisation 
for the Research and Treatment of Cancer Quality of Life Questionnaire head and neck cancer–specific module. EQ-5D-3L=three-level European Quality of 
Life–5 Dimensions questionnaire. LS=least squares. QoL=quality of life. SD=standard deviation. VAS=visual analogue scale. *For the EQ-5D-3L VAS and 
EORTC QLQ-C30 functional and global health/QoL scales, higher baseline values are better. For all other scales, higher baseline values indicate a higher level 
of symptomatology or problems. †For simplification of presentation, all changes from baseline have been ordered such that a positive value indicates 
improvement and a negative value indicates deterioration. ‡Indicates small clinically meaningful deterioration based on thresholds from Cocks et al.32 §Indicates 
large clinically meaningful deterioration based on thresholds from Cocks et al.32 ǁIndicates medium clinically meaningful deterioration based on thresholds from 
Cocks et al.32 ¶Indicates small clinically meaningful improvement based on thresholds from Cocks et al.32 #A negative value indicates an increase in weight gain.








Figure S1: Adjusted mean change from baseline at weeks 9 and 15 in EORTC QLQ-C30 domains overall and 
by baseline PD-L1 expression  
 
Dashed lines indicate clinically meaningful difference (10 points). CI=confidence interval. EORTC QLQ-
C30=European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire–Core 30. 












Figure S2: Adjusted least squares mean change from baseline at weeks 9 and 15 in EORTC QLQ-C30 
domains overall and by baseline p16 status 
 
Dashed lines indicate clinically meaningful difference (10 points). CI=confidence interval. EORTC QLQ-
C30=European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire–Core 30. 
IC=investigator’s choice. LS=least squares. Nivo=nivolumab.  
  








Figure S3: Kaplan-Meier plots of time to first clinically meaningful deterioration for additional domains of 
the EORTC QLQ-C30 among all randomised patients 
 
EORTC QLQ-C30=European Organisation for the Research and Treatment of Cancer Quality of Life 
Questionnaire–Core 30. IC=investigator’s choice.  
  








Figure S4: Adjusted mean change from baseline at weeks 9 and 15 in EORTC QLQ-H&N35 domains overall 
and by PD-L1 expression 
 
Dashed lines indicate clinically meaningful difference (10 points). CI=confidence interval. EORTC QLQ-
C30=European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire head and neck 
cancer–specific module. IC=investigator’s choice. Nivo=nivolumab. PD-L1=programmed death ligand 1. *A 








negative value indicates an increase in weight gain. 
 
Figure S5: Adjusted mean change from baseline at weeks 9 and 15 in EORTC QLQ-H&N35 domains overall 
and by p16 status 
 








Dashed lines indicate clinically meaningful difference (10 points). CI=confidence interval. EORTC QLQ-
H&N35=European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire head and 
neck cancer–specific module. IC=investigator’s choice. LS=least squares. Nivo= nivolumab. *A negative value 
indicates an increase in weight gain. 
  








Figure S6: Time to deterioration (Kaplan-Meier plots of time to first clinically meaningful deterioration, A) 
and Kaplan-Meier estimate of median time to deterioration and HR (95% CI) for the EORTC QLQ-H&N35 
(B) among all randomised patients 
 
CI=confidence interval. EORTC QLQ-H&N35=European Organisation for the Research and Treatment of Cancer 
quality of life questionnaire head and neck cancer–specific module. HR=hazard ratio. IC=investigator’s choice. 
NE=not estimable. Nivo=nivolumab. TTD=time to deterioration. 
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